The decision to eradicate pharma rebates and prompt direct discounts for federal beneficiaries could, if passed, upend the market-what are the critical questions for new products?
A rule to eradicate drug rebates and prompt direct discounts for federal beneficiaries raises challenging questions for drug manufacturers and other stakeholders.